In a nutshell This study aimed to evaluate the effectiveness of nilotinib as a consolidation therapy for patients with chronic myeloid leukemia who had achieved a major response with imatinib. This study concluded that nilotinib led to safer, deeper responses in these patients. Some background Imatinib (Gleevec) is a tyrosine kinase inhibition (TKI)...
Read More
In a nutshell This study evaluated the effectiveness and safety of second-generation tyrosine kinase (TK) inhibitors after imatinib (Gleevec) therapy in children and adolescents with chronic myeloid leukemia (CML). The authors concluded that second-generation TK inhibitors may be a viable first-line treatment option for these patients. Some background...
Read More
In a nutshell This study investigated the vascular (blood vessels) side effects associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML). This study concluded that patients treated with nilotinib (Tasigna) experienced more vascular side effects. Some background Tyrosine kinase (TK) inhibitors are the standard therapy...
Read MoreIn a nutshell This study aimed to investigate the safety of obinutuzumab (Gazyva) in a range of patients with chronic lymphocytic leukemia. This study concluded that obinutuzumab is safe and tolerable for a range of patients with chronic lymphocytic leukemia. Some background Obinutuzumab is a targeted therapy for chronic lymphocytic...
Read More
In a nutshell This study aimed to investigate the effectiveness of nilotinib (Tasigna) as a consolidation therapy for chronic myeloid leukemia patients. This study concluded that nilotinib is safe and effective as a consolidation therapy in these patients. Some background Nilotinib is a targeted therapy used to treat chronic myeloid leukemia...
Read MoreIn a nutshell The study looked at the impact of other medical conditions (comorbidities) on the effectiveness of ibrutinib (Imbruvica) in the treatment of chronic lymphocytic leukemia (CLL). The study concluded that having a number of other conditions was associated with a poorer prognosis in CLL patients treated with ibrutinib. Some background...
Read More
In a nutshell This study aimed to investigate the side effects of tyrosine kinase inhibitors and their impact on outcomes in chronic-phase chronic myeloid leukemia patients. This study concluded that severe side effects from tyrosine kinase inhibitors can cause decreased survival rates in these patients. Some background Tyrosine kinase inhibitors...
Read More
In a nutshell This study aimed to investigate if dasatinib could be successfully discontinued in chronic myeloid leukemia patients who were receiving it as a second line treatment after a year of deep molecular response. This study concluded that it was possible to discontinue dasatinib use in this group of patients. Some background Imatinib...
Read MoreIn a nutshell This study aimed to investigate if side effects of imatinib (Gleevec) treatment in chronic phase chronic myelogenous leukemia would improve if patients were switched to dasatinib (Sprycel) treatment. This study concluded that these patients experience improvements in side effects and quality of life once they switch treatment. Some...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of ponatinib (Iclusig) for patients with chronic phase chronic myelogenous leukemia. This study concluded that ponatinib is safe and effective in this group of patients. Some background The Philadelphia chromosome (BCR-ABL1) is found in almost all patients with chronic...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of dasatinib (Sprycel) and nilotinib (Tasigna) in chronic phase chronic myeloid leukemia patients with failed imatinib (Gleevec) treatment. This study concluded that dasatinib and nilotinib were safe and effective in this group of patients. Some background Chronic...
Read More
In a nutshell This study outlined recent evidence on the use of ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL). Some background Tyrosine kinase inhibitor therapy is a type of immunotherapy that blocks signals needed for tumors to grow. This includes the Bruton tyrosine kinase inhibitor ibrutinib. Ibrutinib blocks a signal that keeps the...
Read More
